Eledon Pharmaceuticals Reports Q1 2025 Progress and Financials

Eledon Pharmaceuticals, Inc. ( (ELDN) ) has released its Q1 earnings. Here is a breakdown of the information Eledon Pharmaceuticals, Inc. presented to its investors.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions, with its lead investigational product being tegoprubart, an anti-CD40L antibody. In its first quarter of 2025, Eledon Pharmaceuticals reported significant progress in its clinical trials, notably using tegoprubart in a successful transplant of a genetically modified pig kidney into a human. The company is on track to report topline results from its Phase 2 BESTOW trial in kidney transplantation by the fourth quarter of 2025, which could potentially demonstrate the superiority of tegoprubart over the standard of care.

Financially, Eledon reported cash, cash equivalents, and short-term investments totaling $124.9 million as of March 31, 2025, with expectations to fund operations through the end of 2026. The company experienced a net loss of $6.5 million for the first quarter, a significant improvement from the $23.6 million loss in the same period of 2024, primarily due to changes in the fair value of warrant liabilities. Research and development expenses increased to $13.5 million, reflecting the company’s ongoing investment in its clinical programs.

Looking ahead, Eledon Pharmaceuticals anticipates several key milestones, including interim data from its Phase 1b trial in August 2025 and results from its Phase 2 BESTOW trial by the end of the year. These developments are expected to further validate tegoprubart’s potential as a novel immunosuppression therapy, positioning the company for significant advancements in the transplant treatment landscape.